<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611403</url>
  </required_header>
  <id_info>
    <org_study_id>192371-014</org_study_id>
    <nct_id>NCT00611403</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients</brief_title>
  <official_title>Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of cyclosporine ophthalmic emulsion
      administered twice daily following LASIK surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Clinical Success at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Percentage of patients with clinical success at month 6. Clinical success is defined as the percentage of patients with corneal sensitivity (the capability of the cornea to respond to stimulation) &gt;= 50 millimeters in all regions of the study eye at month 6 of the Treatment Phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Keratocyte Density in the Anterior Flap of the Eyes at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Change from baseline in keratocyte (specialized cells in the cornea activated after injury or inflammation) density (thickness) in the anterior flap of the eyes (better eye and worse eye) at month 6 of the Treatment Phase. A positive number change from baseline represents an increase in density (improvement). A negative number change from baseline represents a decrease in density (worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Goblet Cell Density of the Eyes at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Change from baseline in goblet cell density of the eyes (better eye and worse eye) at month 6 of the Treatment Phase. Goblet cells are special cells in the eye that support a healthy tear film. A positive number change from baseline represents an increase in goblet cells (improvement).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>RESTASIS®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REFRESH ENDURA®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Artificial Tears (REFRESH ENDURA®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)</intervention_name>
    <description>Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery</description>
    <arm_group_label>RESTASIS®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial Tears REFRESH ENDURA®</intervention_name>
    <description>REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery</description>
    <arm_group_label>REFRESH ENDURA®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is scheduled for bilateral LASIK surgery

          -  Patient is in good general health

          -  Eye glasses prescription of -1 to -8

        Exclusion Criteria:

          -  Significant Dry Eye

          -  Presence of eye disease

          -  Uncontrolled systemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2008</study_first_posted>
  <results_first_submitted>November 17, 2011</results_first_submitted>
  <results_first_submitted_qc>November 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2011</results_first_posted>
  <last_update_submitted>November 17, 2011</last_update_submitted>
  <last_update_submitted_qc>November 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LASIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RESTASIS®</title>
          <description>Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)</description>
        </group>
        <group group_id="P2">
          <title>REFRESH ENDURA®</title>
          <description>Artificial Tears (REFRESH ENDURA®)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Post Treatment Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">26 of 68 pts who received RESTASIS® in the Treatment Phase entered the Post Treatment Ext. Phase</participants>
                <participants group_id="P2" count="25">25 of 69 pts who received ENDURA® in the Treatment Phase entered the Post Treatment Extension Phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RESTASIS®</title>
          <description>Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)</description>
        </group>
        <group group_id="B2">
          <title>REFRESH ENDURA®</title>
          <description>Artificial Tears (REFRESH ENDURA®)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 30 and 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Clinical Success at Month 6</title>
        <description>Percentage of patients with clinical success at month 6. Clinical success is defined as the percentage of patients with corneal sensitivity (the capability of the cornea to respond to stimulation) &gt;= 50 millimeters in all regions of the study eye at month 6 of the Treatment Phase.</description>
        <time_frame>Month 6</time_frame>
        <population>Modified Intent-to-Treat (mITT). The mITT population included all randomized and treated patients with a study eye having a corneal sensitivity measurement of &lt; 25 mm in the 3 central regions of the eye on Day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>RESTASIS®</title>
            <description>Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)</description>
          </group>
          <group group_id="O2">
            <title>REFRESH ENDURA®</title>
            <description>Artificial Tears (REFRESH ENDURA®)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Clinical Success at Month 6</title>
          <description>Percentage of patients with clinical success at month 6. Clinical success is defined as the percentage of patients with corneal sensitivity (the capability of the cornea to respond to stimulation) &gt;= 50 millimeters in all regions of the study eye at month 6 of the Treatment Phase.</description>
          <population>Modified Intent-to-Treat (mITT). The mITT population included all randomized and treated patients with a study eye having a corneal sensitivity measurement of &lt; 25 mm in the 3 central regions of the eye on Day 2.</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3"/>
                    <measurement group_id="O2" value="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Keratocyte Density in the Anterior Flap of the Eyes at Month 6</title>
        <description>Change from baseline in keratocyte (specialized cells in the cornea activated after injury or inflammation) density (thickness) in the anterior flap of the eyes (better eye and worse eye) at month 6 of the Treatment Phase. A positive number change from baseline represents an increase in density (improvement). A negative number change from baseline represents a decrease in density (worsening).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Intent-to-Treat (ITT). The ITT population includes all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>RESTASIS®</title>
            <description>Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)</description>
          </group>
          <group group_id="O2">
            <title>REFRESH ENDURA®</title>
            <description>Artificial Tears (REFRESH ENDURA®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Keratocyte Density in the Anterior Flap of the Eyes at Month 6</title>
          <description>Change from baseline in keratocyte (specialized cells in the cornea activated after injury or inflammation) density (thickness) in the anterior flap of the eyes (better eye and worse eye) at month 6 of the Treatment Phase. A positive number change from baseline represents an increase in density (improvement). A negative number change from baseline represents a decrease in density (worsening).</description>
          <population>Intent-to-Treat (ITT). The ITT population includes all patients who started the study (randomized).</population>
          <units>Cells per cubic millimeter (cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Better Eye: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28095.7" spread="5303.28"/>
                    <measurement group_id="O2" value="26069.5" spread="4648.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Better Eye: Change from Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="901.6" spread="6117.69"/>
                    <measurement group_id="O2" value="1346.6" spread="5550.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse Eye: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26489.9" spread="5161.53"/>
                    <measurement group_id="O2" value="27480.6" spread="4854.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse Eye: Change from Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3011.7" spread="7931.29"/>
                    <measurement group_id="O2" value="-218.4" spread="5799.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Goblet Cell Density of the Eyes at Month 6</title>
        <description>Change from baseline in goblet cell density of the eyes (better eye and worse eye) at month 6 of the Treatment Phase. Goblet cells are special cells in the eye that support a healthy tear film. A positive number change from baseline represents an increase in goblet cells (improvement).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Intent-to-Treat (ITT). The ITT population includes all patients who started the study (randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>RESTASIS®</title>
            <description>Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)</description>
          </group>
          <group group_id="O2">
            <title>REFRESH ENDURA®</title>
            <description>Artificial Tears (REFRESH ENDURA®)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Goblet Cell Density of the Eyes at Month 6</title>
          <description>Change from baseline in goblet cell density of the eyes (better eye and worse eye) at month 6 of the Treatment Phase. Goblet cells are special cells in the eye that support a healthy tear film. A positive number change from baseline represents an increase in goblet cells (improvement).</description>
          <population>Intent-to-Treat (ITT). The ITT population includes all patients who started the study (randomized).</population>
          <units>Cells per square millimeter (cells/mm^2)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Better Eye: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" lower_limit="0" upper_limit="291"/>
                    <measurement group_id="O2" value="59.7" lower_limit="0" upper_limit="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Better Eye: Change from Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9" lower_limit="-284" upper_limit="115"/>
                    <measurement group_id="O2" value="-3.1" lower_limit="-145" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse Eye: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" lower_limit="0" upper_limit="276"/>
                    <measurement group_id="O2" value="79.2" lower_limit="2" upper_limit="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse Eye: Change from Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="-96" upper_limit="222"/>
                    <measurement group_id="O2" value="9.9" lower_limit="-175" upper_limit="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RESTASIS®</title>
          <description>Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)</description>
        </group>
        <group group_id="E2">
          <title>REFRESH ENDURA®</title>
          <description>Artificial Tears (REFRESH ENDURA®)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infected bites</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

